Published in N Engl J Med on October 31, 1991
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med (1999) 11.27
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia (2009) 4.91
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol (2004) 3.49
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med (1984) 3.06
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Flow cytometry in clinical cancer research. Cancer Res (1983) 2.72
Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood (1998) 2.60
Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet (1995) 2.26
Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med (1994) 2.13
Primary dexamethasone treatment of multiple myeloma. Blood (1992) 2.02
Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia (2008) 1.97
VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol (1990) 1.87
Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant (2006) 1.85
Cellular DNA content as a marker of human multiple myeloma. Blood (1980) 1.83
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood (2001) 1.80
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol (1993) 1.76
Malignant pleural effusion of multiple myeloma: prognostic factors and outcome. Leuk Lymphoma (2005) 1.75
Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood (1998) 1.68
Cellular DNA content as a marker of neoplasia in man. Am J Med (1980) 1.62
Graft-versus-myeloma effect: proof of principle. Blood (1996) 1.58
Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood (1998) 1.58
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood (1999) 1.57
Anaplastic myeloma with massive extramedullary involvement. Report of two cases. Cancer (1983) 1.54
Expression of interleukin-6 in Castleman's disease. Hum Pathol (1993) 1.53
Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood (1994) 1.52
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol (1994) 1.49
Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol (1996) 1.46
Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood (1995) 1.45
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia (2012) 1.43
Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol (2001) 1.42
Convention on nomenclature for DNA cytometry. Committee on Nomenclature, Society for Analytical Cytology. Cancer Genet Cytogenet (1984) 1.42
High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood (2000) 1.39
Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood (1995) 1.39
Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia (2012) 1.35
Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant (2006) 1.35
The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia (2009) 1.33
High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood (1986) 1.32
High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med (1991) 1.32
High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med (1986) 1.31
Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood (1999) 1.30
Cytoplasmic immunoglobulin content in multiple myeloma. J Clin Invest (1985) 1.29
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood (1989) 1.29
Correlation of DNA distribution abnormalities with cytogenetic findings in human adult leukemia and lymphoma. Cancer Res (1977) 1.27
Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med (1990) 1.26
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia (2008) 1.25
The growth fraction of human myeloma cells. Blood (1981) 1.24
Age is not a prognostic variable with autotransplants for multiple myeloma. Blood (1999) 1.23
18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. J Clin Oncol (2005) 1.19
Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood (1998) 1.19
In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res (1980) 1.19
Determination of ploidy and proliferative characteristics of human solid tumors by pulse cytophotometry. Cancer Res (1978) 1.18
Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br J Haematol (1997) 1.17
Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol (1990) 1.16
High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood (1987) 1.15
Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood (2001) 1.15
Ploidy and proliferative characteristics in monoclonal gammopathies. Blood (1982) 1.15
Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood (2001) 1.15
Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol (2001) 1.13
Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood (1998) 1.12
Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia (2007) 1.12
Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols. Leukemia (2012) 1.11
Plasma cell karyotype in multiple myeloma. Blood (1988) 1.11
Heterogeneity of non-Hodgkin's lymphoma probed by nucleic acid cytometry. Blood (1985) 1.10
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene (2009) 1.10
Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells. Cancer Res (1981) 1.09
Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br J Haematol (2001) 1.08
Ploidy, proliferative activity and estrogen receptor content in human breast cancer. Cytometry (1982) 1.07
Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol (1997) 1.06
Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol (1998) 1.05
Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations. Leukemia (2006) 1.04
Characterization of hematologic malignancies by flow cytometry. Blood Cells (1980) 1.04
DNA histogram analysis of human hemopoietic cells. Blood (1976) 1.04
Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol (2003) 1.04
Synchronization of mouse L-P59 cells by centrifugal elutriation separation. Exp Cell Res (1977) 1.03
Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant (1998) 1.03
The effect of adriamycin on the cell cycle traverse of a human lymphoid cell line. Cancer Res (1976) 1.03
Immune thrombocytopenia following alpha-interferon therapy in patients with cancer. JAMA (1985) 1.03
Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia (2002) 1.01
Making progress in treating multiple myeloma with total therapies: issue of complete remission and more. Leukemia (2008) 1.01
Prognosis of asymptomatic multiple myeloma. Arch Intern Med (1988) 1.01
Measurement of mammalian sperm deoxyribonucleic acid by flow cytometry. Problems and approaches. J Histochem Cytochem (1977) 1.01
Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant (2005) 1.00
Automatic processing and interpretation of DNA distributions: comparison of several techniques. Comput Biomed Res (1978) 1.00
Effects of cis-dichlorodiammineplatinum(II) on human colon carcinoma cells in vitro. Cancer Res (1979) 0.99
Deletion of the retinoblastoma gene in multiple myeloma. Leukemia (1994) 0.99
High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. J Clin Oncol (1999) 0.98
Fusarium. A newly recognized fungal pathogen in immunosuppressed patients. Cancer (1986) 0.98
Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant (2004) 0.97
Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy. J Rheumatol (1994) 0.97
Flow cytogenetics of uncloned and cloned Chinese hamster cells. Cytogenet Cell Genet (1980) 0.97
Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells. Blood (1995) 0.96
Beta 2 microglobulin in multiple myeloma. Am J Hematol (1985) 0.96
Cure of myeloma: hype or reality? Bone Marrow Transplant (2005) 0.95